Related Experiment Video

Updated: Jan 24, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options

Alexandros Briasoulis1, Chakradhari Inampudi1, Georgios Hatzis1

  • 1Division of Cardiovascular Diseases, Section of Heart Failure and Transplant, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.

Current Medicinal Chemistry
|May 24, 2019
PubMed

Insights

Heart failure (HF) treatments have advanced, improving survival and reducing hospitalizations. New therapies and devices offer further promise for managing this growing cardiovascular disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Devices

Background:

  • Heart failure (HF) prevalence is increasing, driven by an aging population and improved management of other cardiovascular conditions.
  • Despite advances, 5-year mortality rates for HF patients remain a significant concern.
  • Therapeutic options for HF have expanded over recent decades, targeting key pathophysiological mechanisms.

Purpose of the Study:

  • To review recent advancements in heart failure pharmacotherapy and device-based treatments.
  • To discuss emerging therapies and their potential impact on HF outcomes.
  • To highlight the evolving landscape of advanced heart failure management.

Main Methods:

  • Review of recent clinical trials and therapeutic developments in heart failure.
  • Analysis of pharmacological interventions targeting neuro-hormonal activation, neprilysin, and sodium-glucose co-transporter 2.
  • Evaluation of device-based therapies, including left ventricular assist devices (LVADs).

Main Results:

  • Newer medications, including angiotensin receptor-neprilysin inhibitors and f-current inhibitors, have demonstrated efficacy in reducing HF hospitalizations and mortality.
  • Sodium-glucose co-transporter 2 inhibitors show potential for improving HF outcomes.
  • Advanced therapies like cardiac myosin activators and novel LVADs are under investigation.

Conclusions:

  • Current and emerging therapies offer significant improvements in managing heart failure patients.
  • Continued research and clinical trials are essential to validate new strategies, particularly in underrepresented populations.
  • The management of heart failure is rapidly evolving, with a focus on improving both short-term and long-term outcomes.

Keywords:
Heart failureivabradinleft ventricular assist deviceneprylysin inhibitornovel therapysinoatrial pacemaker

More Related Videos

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.8K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
239
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
812
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
751
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
289
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
846